Co. Inc. (NYSE:MRK), reducing the pharmaceutical giant's price target from $105.00 to $96.00, while keeping a Market Perform rating on the stock. Analysts at BMO Capital cited a decrease in confidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback